ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL CANCER INSTITUTE

Career Enhancement Program

Active
Institution
UNIVERSITY OF CALIFORNIA LOS ANGELES, CA
Principal investigator
Linda M Liau
Funding
$9K
Duration
2017–2027
Open portfolio

Moonbase score

Still being scored

Abstract

The studies proposed herein are designed to test the feasibility, safety, and preliminary efficacy of a novel IL-13Ra2/IL-12/DR-18 CAR-T cell therapy for glioblastoma, as well as investigate response biomarkers and mechanisms of immune evasion following the injection of these CAR-T cells intratumorally and intraventricularly. We will test our hypothesis that clinically relevant CAR-T cell therapy for glioblastoma (GBM) must have two components: 1) tumor specific glioblastoma cell targeting; and 2) blockade of the immunosuppressive tumor microenvironment (TME). We believe that our novel IL-13Ra2/IL-12/DR-18 CAR-T cell therapy that simultaneously targets both glioblastoma cells and the immunosuppressive TME may lead to improved outcomes for the treatment of glioblastoma.

LOADING MOONBASE SCORE

NATIONAL CANCER INSTITUTEP50ZCA1-RPRB-Nimmunosuppressiveglioblastomacell therapytmecar-t cellcar-til-il- il-

Questions for UNIVERSITY OF CALIFORNIA LOS ANGELES

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same researchers, same institution, same topic, scored first.